Clinical features and outcomes in patients with human immunodeficiency virus-negative, Castleman’s disease: a single medical center study in Tunisia

1CASTLEMAN B, IVERSON L, MENENDEZ VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956 Jul–Aug;9(4):822-30.Search in Google Scholar

2GABA AR., STEIN RS., SWEET DL., VARIAKOJIS D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 1978 Jan;69(1):86-90.Search in Google Scholar

3MUNSHI N., MEHRA M., VAN DE VELDE H., DESAI A., POTLURI R., VERMEULEN J. Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leuk Lymphoma. 2015 May;56(5):1252-6.Search in Google Scholar

4BONEKAMP D., HORTON KM., HRUBAN RH., FISHMAN EK. Castleman disease: the great mimic. Radiographics. 2011 Oct;31(6):1793-807.Search in Google Scholar

5CRONIN DM., WARNKE RA., Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009 Jul;16(4):236-46.Search in Google Scholar

6MARIA MARTA BIANCHI, FRANCISCO JAVIER, NARVAEZ GARCIA, PILAR SANTO, VALERIA RIOS-RODRIGUEZ, DIANA DE LA FUENTE., et al. Maladie de Castleman multicentrique mimant une maladie de Still de l’adulte. Revue Du Rhumatisme. 2009; 76(5) : 471–474.Search in Google Scholar

7KELLER AR., HOCHHOLZER L., CASTLEMAN B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972 Mar;29(3):670-83.Search in Google Scholar

8TALAT N, BELGAUMKAR AP, SCHULTE KM. Surgery in Castleman’s disease: a systematic review of 404 published cases. Ann Surg. 2012 Apr;255(4):677-84.Search in Google Scholar

9J. YILDIZ., M. BAGCI., S. SAYIN., A. KAYA., F. YILMAZ., O. EKINCI., et al. The clinicopathological features and survival of Castleman disease: A multicenter Turkish study. Eur Rev Med Pharmacol Sci. 2022 Feb;26(4):1131-1137.Search in Google Scholar

10PRIBYL K., VAKAYIL V., FAROOQI N., ARORA N., KREITZ B., IKRAMUDDIN S., et al. Castleman disease: A single-center case series. Int J Surg Case Rep. 2021;80:105650.Search in Google Scholar

11HAAP M., WIEFELS J., HORGER M., HOYER A., MÜSSIG K. Clinical, laboratory and imaging findings in Castleman’s disease – The subtype decides. Blood Rev. 2018; 32(3):225-234Search in Google Scholar

12ERIC OKSENHENDLER, Protocole National de Diagnostic et de Soins (PNDS) Maladie de Castleman, Centre de Reference de la Maladie de Castleman (CRMdC)Search in Google Scholar

13BARANZELLI A., AKKAD R., BOUCHINDHOMME B., TACELLI N., DELOURME J., DHALLUIN X., et al. La maladie de Castleman : observations inhabituelles et revue de la littérature. Revue de Pneumologie Clinique.2013, 69(1) : 55–59.Search in Google Scholar

14V. MEIGNIN., M. PARRENS. La maladie de Castleman : aspects anatomopathologiques. La Revue de Médecine Interne, 2022; 43(10): 10S10-10S16.Search in Google Scholar

15PALMIC, P., BRUNEAU, J., CANIONI, D., BRIERE, J., & JO MOLINA, T. Maladie de Castleman multicentrique idiopathique : comment faire le diagnostic ? Revue Francophone Des Laboratoires, 2020(518), 52–57.Search in Google Scholar

16BORIE, R., RIQUET, M., DANEL, C., CRESTANI, B., MORDANT, P. Maladie de Castleman médiastinale : mise au point. Revue de Pneumologie Clinique, 2013; 69(6) : 354–357.Search in Google Scholar

17BARKER R, KAZMI F, BOWER M. Imaging in multicentric Castleman’s disease. J HIV Ther. 2008; 13(3):72-4.Search in Google Scholar

18BARKER R., KAZMI F., STEBBING J., NGAN S., CHINN R., NELSON M., et al. FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman’s disease. Eur J Nucl Med Mol Imaging. 2009;36(4): 648-52.Search in Google Scholar

19A. GONZALEZ GARCIA., W.A. SIFUENTES GIRALDO., MARIA AHIJON LANA., JOSE LUIS PATIER DE LA PEÑA. Autoimmune manifestations in patients with multicentric Castleman’s disease, Annals of the Rheumatic Diseases. 2014; 73(2) : 308.2-308.Search in Google Scholar

20KOJIMA M., NAKAMURA S., MORISHITA Y., ITOH H, YOSHIDA K., OHNO Y., et al. Reactive follicular hyperplasia in the lymph node lesions from systemic lupus erythematosus patients: a clinicopathological and immunohistological study of 21 cases. Pathol Int. 2000; 50 (4):304–312.Search in Google Scholar

21KOJIMA M., MOTOORI T., ASANO S., NAKAMURA S. Histological diversity of reactive and atypical proliferative lymph node lesions in systemic lupus erythematosus patients. Pathol Res Pract. 2007;203(6): 423-31.Search in Google Scholar

22DE MARCHI G., DE VITA S., FABRIS M., SCOTT CA., FERRACCIOLI G. Systemic connective tissue disease complicated by Castleman’s disease: report of a case and review of the literature. Haematologica. 2004;89(4).Search in Google Scholar

23SOULIER J., GROLLET L., OKSENHENDLER E., CACOUB P., CAZALS-HATEM D, BABINET P., et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86(4):1276-80.Search in Google Scholar

24V. MEIGNIN., M. PARRENS. La maladie de Castleman: aspects anatomopathologiques. La Revue de Médecine Interne. 2022; 43(10): 10S10-10S16.Search in Google Scholar

25LATOUR S. Natural killer T cells and X-linked lymphoproliferative syndrome. Curr Opin Allergy Clin Immunol. 2007;7(6):510-4.Search in Google Scholar

26VÉRONIQUE MEIGNIN., JULIEN CALVANI., ERIC OKSENHENDLER. La maladie de Castleman. Annales de Pathologie.2023;43 (1): 13-24.Search in Google Scholar

27VIALLARD JF., RORIZ M, PARRENS M., BONNOTTE B. Diagnostics différentiels de la maladie de Castleman. Rev Med Interne.2022;43(10S1):10S17-10S25.Search in Google Scholar

28DISPENZIERI A., FAJGENBAUM DC. Overview of Castleman disease. Blood. 2020; 135(16):1353-1364.Search in Google Scholar

29OKSENHENDLER E., BOULANGER E., GALICIER L., DU MQ., DUPIN N., DISS TC., et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99(7):2331-6.Search in Google Scholar

30ISHII T., TATEKAWA T., KOSETO M., ISHII M., KOBAYASHI H., KOIKE M., et al. A case of multicentric Castleman’s disease demonstrating severe eosinophilia and enhanced production of interleukin-5. Eur J Haematol. 2003;70(2):115-8.Search in Google Scholar

31DHINGRA H, SONDHI D, FLEISCHMAN J, AYINLA R, CHAWLA K, ROSNER F. Castleman’s disease and superior vena cava thrombi: a rare presentation and a review of the literature. Mt Sinai J Med. 2001;68(6):410-6.Search in Google Scholar

32VAN RHEE F., GREENWAY A., STONE K. Treatment of Idiopathic Castleman Disease. Hematol Oncol Clin North Am. 2018;32(1):89-106.Search in Google Scholar

33VAN RHEE F., VOORHEES P., DISPENZIERI A., FOSSÅ A., SRKALOVIC G., IDE M., et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115-2124.Search in Google Scholar

34VAN RHEE F., CASPER C., VOORHEES PM., FAYAD LE., GIBSON D., KANHAI K., et al. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: A prespecifed, openlabel, extension analysis of two trials. Lancet Haematol. 2020;7(3): e209-e217.Search in Google Scholar

35TALAT N., SCHULTE KM. Castleman’s disease: systematic analysis of 416 patients from the literature. Oncologist. 2011;16(9):1316-24.Search in Google Scholar